New drug combo targets hidden inflammation in heart patients

NCT ID NCT06097663

First seen Mar 27, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This study tested two experimental drugs, DFV890 (a daily pill) and MAS825 (a single shot), to see if they could lower inflammation in 31 adults with coronary heart disease and a genetic blood condition called CHIP. The goal was to reduce markers like IL-6 and IL-18 that are linked to heart risks. The study was completed, but results are not yet public.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Montreal, Quebec, H1T 1C8, Canada

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    München, 80636, Germany

  • Vanderbilt University Medical Cent

    Nashville, Tennessee, 37232-8805, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.